BFBIO news and notes BF Biosciences Limited
BF Biosciences Limited (BFBIO) news and notes: the SuperX note and what changed (4 items). The note is written by SuperX’s AI from its own figures. What changed is listed newest first.
What SuperX wrote about BFBIO
BFBIO fell 0.74% on 20 Nov, with volume at 0.54 times its usual level. The pharmaceuticals sector median was flat, with 7 scrips up and 8 down.
On 4 Nov the price rose 4.11% on 1.51 times the usual volume. The whole pharmaceuticals sector rose too, and foreign investors bought on net.
The company filed its half-year results for the period ending 31 Dec on 26 Feb last year, a year ago.
Written by SuperX’s analyst desk from SuperX’s own figures, from the close of 20 Nov 2026. Each number was checked against those figures. Not advice.
What changed for BFBIO, newest first
- 20 Nov 2026Closed 137.22, -0.74%. Volume 68,055, 0.4 times the average of the 30 sessions before it, 196,476.
- 4 Nov 2026Trend read changed to leaning up: above the 50-day average; up 8.5% over 1 month.
- 28 Oct 2026Quarter ended 30 Sep 2026: earnings per share Rs 2.09, sales Rs 2.8 bn, up 15.5% on the same quarter a year before.
- NextHalf-year results (to 31 Dec 2026) expected 22 Feb 2027 – 4 Mar 2027, a projection. An estimate from the dates of the last 2 filings.
As of the close of 20 Nov 2026. Closes and notices: PSX. Trend read: SuperX, from daily closes. Volume: against the average of the 30 sessions before the last. Next results: an estimate from the dates of the last 2 filings. Not advice.
More on BFBIO
- BFBIO share price and overview
- Pharmaceuticals sector
- CPHL news and notes · Citi Pharma Ltd.
- HALEON news and notes · Haleon Pakistan Limited
Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .